What is TuHURA Biosciences's earnings per share (EPS)?

TuHURA Biosciences (HURA) reported diluted earnings per share of $-0.63 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

TuHURA Biosciences Financials

HURA

Source SEC Filings (10-K/10-Q) Updated May 15, 2026 Currency USD FYE December

This page shows TuHURA Biosciences (HURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HURA FY2025 2026-04-30

TuHURA is operating as a capital-funded research platform, with FY2025 cash burn overwhelming new financing and shrinking liquidity.

FY2025's larger asset base hid a sharper cash squeeze: after $19.9M of financing inflow, cash still ended the year at just $3.6M. Operating cash burn nearly doubled from FY2024 to $27.6M as R&D rose to $20.5M, so the business became more dependent on fresh capital even while reported assets increased.

Cash burn was operational, not capital-heavy: free cash flow of -$27.7M closely tracked operating cash flow of -$27.6M. With capex only $76K, the cash drain came from running the research program rather than building a capital-heavy operating base.

Short-term liquidity tightened faster than solvency: the current ratio fell from 3.7x to 0.8x, leaving current assets short of current liabilities. At the same time, goodwill reached $10.7M while cash was only $3.6M, so a bigger balance sheet did not translate into more spending flexibility.

Financial Health Signals

Financial Profile 18/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of TuHURA Biosciences's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

TuHURA Biosciences carries a low D/E ratio of 0.31, meaning only $0.31 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

TuHURA Biosciences's current ratio of 0.78 is below the typical benchmark, resulting in a score of 10/100. However, the company holds substantial cash reserves (61% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Returns

TuHURA Biosciences generates a -143.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -148.6% the prior year.

Piotroski F-Score Weak

1/9

TuHURA Biosciences passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, TuHURA Biosciences generates $0.92 in operating cash flow (-$27.6M OCF vs -$30.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

TuHURA Biosciences generated $0 in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$30.1M

YoY-38.6%

TuHURA Biosciences reported -$30.1M in net income in fiscal year 2025. This represents a decrease of 38.6% from the prior year.

EPS (Diluted)

$-0.63

TuHURA Biosciences earned $-0.63 per diluted share (EPS) in fiscal year 2025. This represents an increase of 47.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$27.7M

YoY-87.4%

TuHURA Biosciences generated -$27.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 87.4% from the prior year.

Cash & Debt

$3.6M

YoY-71.4%

5Y CAGR+8.6%

10Y CAGR+7.5%

TuHURA Biosciences held $3.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

59M

TuHURA Biosciences had 59M shares outstanding in fiscal year 2025. This represents an increase of 387.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-143.6%

YoY+5.0pp

5Y CAGR+3326.4pp

TuHURA Biosciences's ROE was -143.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$20.5M

YoY+54.0%

5Y CAGR+41.4%

10Y CAGR+23.2%

TuHURA Biosciences invested $20.5M in research and development in fiscal year 2025. This represents an increase of 54.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$76K

YoY+31.4%

TuHURA Biosciences invested $76K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 31.4% from the prior year.

HURA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0	$0	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$20.5M+54.0%	$13.3M+41.8%	$9.4M-38.0%	$15.2M+28.4%	$11.8M+225.5%	$3.6M
SG&A Expenses	$7.6M+95.8%	$3.9M-6.5%	$4.1M-44.8%	$7.5M-23.0%	$9.8M+116.1%	$4.5M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$625K-84.9%	$4.1M+22044.2%	$19K	N/A	$30K	N/A
Income Tax	$2K-57.5%	$4K	$0	N/A	N/A	N/A
Net Income	-$30.1M-38.6%	-$21.7M	N/A	-$22.7M+40.8%	-$38.3M-319.7%	-$9.1M
EPS (Diluted)	$-0.63	$-1.21	$-2.47	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.2M	N/A	$5.0M+0.8%	$4.9M+7.5%	$4.6M	N/A	$2.9M+4.4%	$2.8M
SG&A Expenses	$2.3M	N/A	$1.8M-64.4%	$4.9M+103.2%	$2.4M	N/A	$783K-1.5%	$796K
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$28K	N/A	$17K	N/A	N/A	N/A	$2.0M+47.5%	$1.4M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.5M	N/A	-$7.1M+25.4%	-$9.5M-42.9%	-$6.7M	N/A	-$5.6M-6.0%	-$5.3M
EPS (Diluted)	$-0.13	N/A	$-0.14+33.3%	$-0.21-40.0%	$-0.15	N/A	$-0.54-25.6%	$-0.43

HURA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$27.4M+37.0%	$20.0M+357.8%	$4.4M-72.6%	$15.9M+17.8%	$13.5M+361.0%	$2.9M
Current Assets	$4.6M-76.4%	$19.6M+371.5%	$4.2M-68.6%	$13.3M+12.4%	$11.8M+313.6%	$2.9M
Cash & Equivalents	$3.6M-71.4%	$12.7M+245.3%	$3.7M-68.9%	$11.8M+11.8%	$10.5M+340.5%	$2.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$10.7M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.4M+19.5%	$5.4M-9.3%	$5.9M+42.6%	$4.2M+40.2%	$3.0M+10.7%	$2.7M
Current Liabilities	$5.9M+11.1%	$5.3M+48.2%	$3.6M-9.9%	$4.0M+43.5%	$2.8M+3.9%	$2.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$20.9M+43.4%	$14.6M+1036.3%	-$1.6M-113.2%	$11.8M+11.5%	$10.6M+3923.2%	$263K
Retained Earnings	-$141.2M-27.1%	-$111.1M-25.6%	-$88.5M+35.1%	-$136.4M-22.6%	-$111.2M-59.5%	-$69.7M

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$29.7M+8.6%	$27.4M+6.4%	$25.7M-25.8%	$34.6M+136.5%	$14.6M-26.7%	$20.0M+382.3%	$4.1M-33.2%	$6.2M
Current Assets	$7.0M+51.1%	$4.6M+31.9%	$3.5M-72.1%	$12.5M-12.5%	$14.3M-27.0%	$19.6M+463.0%	$3.5M-37.0%	$5.5M
Cash & Equivalents	$6.3M+74.0%	$3.6M+34.2%	$2.7M-68.3%	$8.5M+36.9%	$6.2M-50.9%	$12.7M+319.1%	$3.0M-38.5%	$4.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$10.7M0.0%	$10.7M-20.8%	$13.6M0.0%	$13.6M	N/A	N/A	N/A	N/A
Total Liabilities	$6.5M+1.5%	$6.4M-28.0%	$8.9M-41.2%	$15.2M+217.3%	$4.8M-11.0%	$5.4M-22.2%	$6.9M-47.5%	$13.2M
Current Liabilities	$6.1M+2.5%	$5.9M-33.0%	$8.8M-41.8%	$15.2M+217.3%	$4.8M-10.3%	$5.3M+136.2%	$2.3M-0.1%	$2.3M
Long-Term Debt	$1.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$23.2M+10.8%	$20.9M+24.8%	$16.8M-13.7%	$19.4M+97.3%	$9.9M-32.5%	$14.6M+627.4%	-$2.8M+60.2%	-$7.0M
Retained Earnings	-$148.7M-5.3%	-$141.2M-5.0%	-$134.4M-5.6%	-$127.3M-8.1%	-$117.8M-6.0%	-$111.1M+31.4%	-$162.1M-1.4%	-$159.9M

HURA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$27.6M-87.6%	-$14.7M-23.2%	-$12.0M+41.4%	-$20.4M-8.1%	-$18.9M-137.9%	-$7.9M
Capital Expenditures	$76K+31.4%	$58K-26.9%	$79K-56.0%	$180K	N/A	N/A
Free Cash Flow	-$27.7M-87.4%	-$14.8M-22.9%	-$12.0M+41.5%	-$20.6M	N/A	N/A
Investing Cash Flow	-$1.3M+77.9%	-$6.1M-366.7%	-$1.3M	N/A	$964K	N/A
Financing Cash Flow	$19.9M-33.1%	$29.8M+1019.2%	$2.7M-87.7%	$21.6M-16.9%	$26.0M+294.5%	$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$25K	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$4.4M+20.6%	-$5.6M+49.9%	-$11.1M-77.4%	-$6.2M-31.9%	-$4.7M-82.3%	-$2.6M-37.6%	-$1.9M+62.7%	-$5.1M
Capital Expenditures	$49K+75.4%	$28K	$0-100.0%	$6K-87.0%	$43K+99.3%	$21K	$0	N/A
Free Cash Flow	-$4.5M+20.1%	-$5.6M+49.6%	-$11.1M-77.3%	-$6.3M-30.8%	-$4.8M-82.4%	-$2.6M-38.8%	-$1.9M	N/A
Investing Cash Flow	-$49K-75.4%	-$28K	$0+100.0%	-$156K+86.4%	-$1.2M-39.8%	-$824K+84.1%	-$5.2M	N/A
Financing Cash Flow	$7.1M+9.7%	$6.5M+23.4%	$5.3M-39.4%	$8.7M+1687.5%	-$548K+84.4%	-$3.5M-122.4%	$15.7M+21.3%	$13.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HURA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-143.6%+5.0pp	-148.6%	N/A	-192.1%+169.8pp	-361.9%+3108.0pp	-3470.0%
Return on Assets	-109.9%-1.3pp	-108.6%	N/A	-142.1%+140.7pp	-282.8%+27.8pp	-310.6%
Current Ratio	0.78-2.9	3.68+2.5	1.16-2.2	3.32-0.9	4.24+3.2	1.07
Debt-to-Equity	0.31-0.1	0.37+4.2	-3.80-4.2	0.35+0.1	0.28-9.9	10.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-32.5%	N/A	-42.3%+6.6pp	-49.0%+18.6pp	-67.6%	N/A	N/A	N/A
Return on Assets	-25.4%	N/A	-27.6%-0.1pp	-27.5%+18.0pp	-45.5%	N/A	-134.8%-49.9pp	-84.9%
Current Ratio	1.15+0.4	0.78+0.4	0.40-0.4	0.83-2.2	3.00-0.7	3.68+2.1	1.54-0.9	2.45
Debt-to-Equity	0.07-0.2	0.31-0.2	0.53-0.2	0.78+0.3	0.49+0.1	0.37+2.9	-2.50-0.6	-1.89
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Io Biotech, Inc. IOBT

$3.5M

Oncolytics Biotech Inc ONCY

$101.4M

Pyxis Oncology, Inc. PYXS

$138.9M

Avalo Therapeutics Inc AVTX

$999.3M

Skye Bioscience SKYE

$30.6M

Frequently Asked Questions

What is TuHURA Biosciences's annual revenue?

TuHURA Biosciences (HURA) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is TuHURA Biosciences profitable?

No, TuHURA Biosciences (HURA) reported a net income of -$30.1M in fiscal year 2025.

What is TuHURA Biosciences's return on equity (ROE)?

TuHURA Biosciences (HURA) has a return on equity of -143.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is TuHURA Biosciences's free cash flow?

TuHURA Biosciences (HURA) generated -$27.7M in free cash flow during fiscal year 2025. This represents a -87.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is TuHURA Biosciences's operating cash flow?

TuHURA Biosciences (HURA) generated -$27.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are TuHURA Biosciences's total assets?

TuHURA Biosciences (HURA) had $27.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are TuHURA Biosciences's capital expenditures?

TuHURA Biosciences (HURA) invested $76K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does TuHURA Biosciences spend on research and development?

TuHURA Biosciences (HURA) invested $20.5M in research and development during fiscal year 2025.

How many shares does TuHURA Biosciences have outstanding?

TuHURA Biosciences (HURA) had 59M shares outstanding as of fiscal year 2025.

What is TuHURA Biosciences's current ratio?

TuHURA Biosciences (HURA) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is TuHURA Biosciences's debt-to-equity ratio?

TuHURA Biosciences (HURA) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TuHURA Biosciences's return on assets (ROA)?

TuHURA Biosciences (HURA) had a return on assets of -109.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is TuHURA Biosciences's cash runway?

Based on fiscal year 2025 data, TuHURA Biosciences (HURA) had $3.6M in cash against an annual operating cash burn of $27.6M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is TuHURA Biosciences's Piotroski F-Score?

TuHURA Biosciences (HURA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TuHURA Biosciences's earnings high quality?

TuHURA Biosciences (HURA) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is TuHURA Biosciences?

TuHURA Biosciences (HURA) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.